|
|
Agenerase (Amprenavir)
| Brand Name: |
Agenerase |
| Generic Name: |
Amprenavir, APV |
| Adult Single Dose: |
Eight 150-mg capsules (twice a day)
OR eight 150-mg capsules plus two 100-mg ritonavir capsules (once a
day) OR four 150-mg capsules plus one 100-mg ritonavir capsule (twice
a day) |
| Food & Liquid Restrictions: |
May be taken with or without food. High-fat meals should be avoided.
|
| Drug Class: |
PI |
The Basics
News
- Agenerase (Amprenavir) Oral Solution and 50-mg Capsules to Be Discontinued in the U.S. (October 2007)
To read PDF, click here
From GlaxoSmithKline
- FDA Bits: 3TC, Amprenavir and Nandrolone (September 2002)
[Archived Article]
Once-a-day dosing for 3TC (Epivir) approved; new interaction warnings for amprenavir (Agenerase); nandrolone decanoate returns to the U.S. market.
In HIV Treatment ALERTS!, from The Center for AIDS
- FDA Approves New Dosing for Amprenavir and Ritonavir Combination (March 8, 2002)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
- New Dosing Regimen for Agenerase and Norvir (February 13, 2002)
[Archived Article]
To read PDF, click here
In STEP Ezine, from Seattle Treatment Education Project
- Amprenavir Oral Solution Warning (March 2001)
[Archived Article]
In What's New, from Project Inform
- What's New in Treatment Information? Amprenavir Oral Solution Warning (June 2000)
[Archived Article]
In What's New, from Project Inform
- Amprenavir (Agenerase®) Oral Solution: Warning for Some Patients (May 5, 2000)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
- New Safety Warning for Liquid Amprenavir (May 5, 2000)
[Archived Article]
In STEP Ezine, from Seattle Treatment Education Project
- Treatment Briefs: Agenerase Oral Solution Warning (Spring 2000)
[Archived Article]
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Dose Adjustments When Using Amprenavir (September 1999)
[Archived Article]
In Project Inform Perspective, from Project Inform
- Amprenavir Approved: New (Possible) 2nd Generation PI Hits the Market (Summer 1999)
[Archived Article]
In STEP Perspective, from Seattle Treatment Education Project
- Fifth Protease Inhibitor Approved (June 1999)
[Archived Article]
In Body Positive, from Body Positive
- Amprenavir, New Protease Inhibitor, Approved (May 7, 1999)
[Archived Article]
From AIDS Treatment News
- FDA Approves an AIDS Drug From Vertex (April 19, 1999)
[Archived Article]
Approval of Agenerase, the fifth drug targeting HIV's protease enzyme.
From U.S. Centers for Disease Control and Prevention
- FDA Approves Amprenavir for HIV Infection (April 16, 1999)
[Archived Article]
From U.S. Food and Drug Administration
Research
- Dosing Agenerase + Kaletra -- Trying to Juggle, Walk and Chew Gum All at the Same Time (March/April 2004)
A study presented at CROI 2004 bolsters support for the use of therapeutic drug monitoring to customize dosing.
In Positively Aware, from Test Positive Aware Network
- Using Genotypic Inhibitory Quotient to Measure Response to Boosted-Amprenavir Regimen (July 15, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- GW433908 in ART-Naive Subjects: Absence of Resistance at 48 Weeks With Boosted Regimen and APV-Like Resistance Profile With Unboosted Regimen (February 11, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Fosamprenavir Enters the Home Stretch (December 2002)
[Archived Article]
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Research From the 42nd ICAAC: Resistance Tests Compared; Amprenavir Is Guinea Pig (December 2002)
[Archived Article]
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- A Population Based-Analysis of Amprenavir Trough Concentrations Assessed in the Course of Therapeutic Drug Monitoring (November 21, 2002)
[Archived Article]
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
- Abacavir/Lamivudine in Combination With Efavirenz, Amprenavir/Ritonavir or Stavudine: ESS40001 (CLASS) Preliminary 48-Week Results (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Efficacy and Safety of Amprenavir/Ritonavir 600/100 mg BID Compared to APV 1,200 mg BID in ART-Experienced and Naive Subjects: ESS40011 (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Potency and Tolerability of Once-a-Day, Directly Observed Therapy for Inner-City, Minority Patients (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Preliminary Results of Intensification Therapy With Amprenavir/Ritonavir in Two Different Doses: 1,200/200 QD vs. 600/100 BID in Heavily Pretreated Patients Failing HAART (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Decreased Plasma Concentrations of Amprenavir and Lopinavir in HIV Patients on This Combination (July 8, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- A New Look at Liver Toxicity Development During Antiretroviral Therapy Containing Protease Inhibitors in Patients With HIV (March 11, 2002)
[Archived Article]
To read PDF, click here
In STEP Ezine, from Seattle Treatment Education Project
- Amprenavir and Lipodystrophy (March 2002)
[Archived Article]
In Project Inform Perspective, from Project Inform
- An Assessment of Plasma Amprenavir (APV) Pharmacokinetics (PK) Following Administration of Two GW433908 (908) and Ritonavir (RTV) Regimens in Combination With Efavirenz (EFV) in Healthy Adult Subjects (APV10010) (February 27, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Molecular Mechanism of I50V, I54L and I54M Resistance to Amprenavir and Other HIV-1 Protease Inhibitors (February 26, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- In Vitro Model for Antiviral Activity for Amprenavir (APV)/Ritonavir (RTV) (December 19, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Efficacy, Safety and Amprenavir: Pharmacokinetic Responses of Twice-Daily APV and Ritonavir Regimens in HIV-1 Infected Treatment-Experienced Adults for 48 Weeks (ESS40006) (December 18, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Impact on Fitness Conferred by Amprenavir Resistance Mutations (December 18, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Variations in HIV-1 Gag p6 Contribute to the Amprenavir-Specific Protease I50V Resistance Pathway (December 18, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Amprenavir (APV) Plasma and Intracellular Concentrations When Co-Administered With Ritonavir (RTV) in Twice- and Once-Daily Regimens in HIV-Infected Patients (December 16, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Novel Resistance Pattern Suggests Amprenavir May Be Unique After All (November 2001)
[Archived Article]
In HEPP News, from Brown Medical School
- Clinical Experience of Amprenavir (APV) Following Nelfinavir (October 27, 2001)
[Archived Article]
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- Final Results of a Pilot, 48-Week Study of Amprenavir/Abacavir/Lamivudine (APV/ABC/3TC) in ART-Naive Subjects with HIV-1 Infection (October 27, 2001)
[Archived Article]
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- Differential In Vitro Effects of Indinavir, Nelfinavir and Amprenavir On Cell Differentiation, Insulin Sensitivity and Apoptosis in an Adapted Adipose Cell Model -- Preventive Impact of Rosiglitazone (October 25, 2001)
[Archived Article]
In 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO
- Prevalence of Phenotypic Resistance to Amprenavir in Protease-Inhibitor-Experienced Patients: Data from CNAB3008 (July 10, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Abacavir, Lamivudine and Amprenavir +/- Ritonavir Is a Potent and Well-Tolerated HAART Regimen in Therapy-Naive Subjects (Preliminary Results from GW Protocols) (COL30325) (July 9, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Comparison of QD Protease Inhibitors (PIs): Estimated Cmin/IC50 (IQ) After Missed Dose Shows Agenerase Advantage (July 9, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Influence of 50 mg, 100 mg and 200 mg of Ritonavir (RTV) on the Pharmacokinetics (PK) of Amprenavir (APV) After Multiple Doses in Healthy Volunteers for Once-Daily (QD) and Twice-Daily (BID) Regimens (July 9, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Monitoring Intracellular HIV-1 Replication in Blood and Lymphoid Tissue in Antiretroviral Naive Subjects Receiving Amprenavir (APV), Abacavir (ABC), and 3TC (COLA3003 Study) (July 9, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Use of Trizivir to Simplify Therapy in HAART-Experienced Patients With Long-Term Suppression of HIV-RNA: TRIZAL Study (AZL30002) -- 24-Week Results (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Therapeutic Drug Monitoring of Amprenavir Combined With Ritonavir as Salvage Therapy in HIV-1-Infected Patients (July 11, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
|
Advertisement
|
E-Mail
Glossary
Share